Evidence map›Paper›PMID 42090119›Full record

ArticleAnnals of biomedical engineering2026

An In Silico Patient-Specific Computational Framework for a Tissue-Engineered Pulmonary Valve Using Fluid-Structure Interaction Analysis.

Fabrizio Crascì, Tahir Turgut, Maria Bastrom, Deniz Oztruk, Nils Götzen, Martijn Cox, Salvatore Pasta

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fabrizio CrascìDepartment of Engineering, Università degli Studi di Palermo, Viale delle Scienze Ed.8, Palermo, Italy.ORCID http://orcid.org/0009-0008-8824-884X
Tahir Turgut4RealSim Services BV, Groene Dijk 2B, 3401 NJ, IJsselstein, Netherlands.
Maria BastromCapvidia, Technologielaan 3, 3001, Leuven, Belgium.
Deniz OztrukCapvidia, Technologielaan 3, 3001, Leuven, Belgium.
Nils GötzenDepartment of Research, IRCCS, ISMETT, via Tricomi, 5, Palermo, Italy.
Martijn CoxXeltis BV, De Lismortel 31, 5612AR, Eindhoven, The Netherlands.
Salvatore PastaDepartment of Engineering, Università degli Studi di Palermo, Viale delle Scienze Ed.8, Palermo, Italy. salvatore.pasta@unipa.it.ORCID http://orcid.org/0000-0002-4841-2560

Funding

H2020 Excellent Science 101017523
6 · The paper itself

Abstract

Tissue-engineered heart valves provide significant promise for pediatric patients by overcoming the shortcomings of existing prostheses, which do not accommodate the patients' growth. The Xeltis pulmonary valve (XPV) has recently shown promising clinical outcomes for endogenous tissue restoration in pediatric patients with congenital heart diseases. In this context, patient-specific computational modeling may be pivotal in the advancement and clinical application of in situ polymer-based cardiac valves, enhancing design, facilitating regulatory approval, and diminishing dependence on preclinical animal testing. This study seeks to establish a computational framework for incorporating the XPV device into patient-specific models and assessing the device's biomechanical performance via fully coupled fluid-structure interaction (FSI) simulations. Hemodynamic parameters were predicted and compared with echocardiographic data from the prior Xeltis clinical trial. FSI analyses showed good agreement with clinical assessments, with errors in the device's transmural pressure gradient ≤ 10%. Simulations further confirmed that XPV maintains favorable hemodynamics and mechanical integrity throughout the cardiac cycle. This computational framework can facilitate design optimization and tailored implantation strategies for innovative tissue-engineered heart valves. Although further validation with extensive clinical data is required to confirm the model's credibility, this framework provides a foundation for in silico trials to evaluate the long-term restorative performance of the XPV device.

Indexed as

Fluid-structure interaction analysisPulmonary valveTissue-engineered heart valvesValidation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.